ITALIANO (ITALIAN)
Abbott Header Logo
Logo Image

Torch testing

Get in Touch
Torch background image
Torch background image
Torch background image

Congenital infections

When you are pregnant, your greatest priority is protecting your baby. Congenital infections are caused by several pathogens that can be transmitted from the mother to the baby. These infections cause little to no symptoms in healthy adults; however, they severely affect the unborn fetus or newborn baby. Therefore, screening for these pathogens can help reduce the risk of fetal death and potentially life-threatening adverse effects. 

Abbott offers reliable and accurate TORCH testing solutions that can differentiate and help identify congenital infections early. TORCH is an acronym for a group of infections that can be transmitted from the mother to the baby during pregnancy, during childbirth, or shortly after birth:  Toxoplasma gondii, Rubella, Cytomegalovirus (CMV), Herpes Simplex Virus (HSV), and other infections such as syphilis.1

 For in vitro diagnostic use.

10-30%

of all stillbirths have infectious etiology2

~3%

of live births have congenital anomalies present2

Depending on the pathogen

Up to 50%

of pregnancies with congenital infections may result in loss of a baby or fetal death2

Torch testing: every baby deserves a healthy beginning

Healthcare providers are commonly challenged with unknown or potentially serious cases of prenatal infection.

Serological testing can help quickly confirm infection and substantially help reduce the risk of infection to the mother and a baby.

TOrch container bgd img
TOrch container bgd img

Torch barriers

Reducing the burden of congenital infections can be accomplished by overcoming some basic challenges.

Early detection3

Early screening can play a role in the early identification of TORCH infections which may help reduce the risk of complications and life-threatening adverse effect to the baby.

Infection awareness

Knowing one’s infection status can help increase the probability for receiving early treatment and valuable education on safe practices to reduce the risk of exposure.

Testing guidelines

Many patients fail to be tested due to the absence of clear guidelines. Heightened global awareness among clinicians and the general population can accelerate early detection.

Torch panel value

Harness the power of Abbott's torch panel to streamline testing, elevate performance, and help increase the probability of confidently identifying congenital infections.

Confident results

  • Highly specific assays
  • High sensitivity for the early detection of infection
  • Easy interpretation of results
  • Full automation from primary tube to result minimizes the chance of human error
  • Ready-to- use calibrators and controls reduces the possibility of reconstitution errors

Optimized efficiency

  • Consolidation of TORCH assays on Alinity i and ARCHITECT
  • Streamlines testing – minimizes hands-on time
  • Quick results reduce turn-around times
  • Highly specific assays - avoid re-runs and confirmation testing
  • Wide array of sample types: serum and plasma
Abbott's assays

Toxo IgM | Toxo IgG | Toxo IgG Avidity | Rubella IgM | Rubella IgG 

CMV IgM | CMV IgG | CMV IgG Avidity | HSV-1 IgG | HSV-2 IgG

 

TOrch container bgd img
TOrch container bgd img

Supporting
Publications

Learn more about the performance of Abbott's TORCH assays from peer reviewed journals.

Check back for more resources.

PUBLICATIONDESCRIPTION
IgG Avidity Test to Discriminate between Acute and Chronic Toxoplasmosis
Evaluation of the Abbott's ARCHITECT Avidity assay in detecting latent infection in the presence of persistent IgM.
Comparative evaluation of the ARCHITECT Toxo IgG, IgM and IgG Avidity assays for anti-Toxoplasma antibodies detection in pregnant women sera
Study highlights the value of the Abbott's ARCHITECT for the analysis of all clinical situations concerning Toxoplasma gondii serology.
Multicentric evaluation of two chemiluminescent immunoassays for IgG and IgM antibodies towards Rubella virus
An Italian study published in the Journal of Clinical Virology highlights the performance of the ARCHITECT analyzer in comparison with other commercial methods.
Evaluation of the New ARCHITECT Cytomegalovirus Immunoglobulin M (IgM), IgG, and IgG Avidity Assays
A team of researchers from Belgium evaluates the ARCHITECT CMV immunoassays with several well-established comparator assays.
Evaluation of the Abbott ARCHITECT cytomegalovirus IgG/IgM, rubella IgG/IgM, and syphilis treponemal enzyme immunoassays in a mother and child health center population
Researchers from Montreal, Quebec, Canada assessed chemiluminescent microparticle immunoassays in mixed pediatric and women of childbearing age population.
Comparison of the two fully automated anti-HCMV assays: Abbott ARCHITECT CMV IgG assay and Biotest anti-HCMV recombinant IgG ELISA
A study published in Transfusion Medicine assessed the performance of CMIA and ELISA immunoassays under routine conditions in a transfusion laboratory.
Kinetics of CMV seroconversion in a Swiss pregnant population
Evaluation of CMV serology to determine the utility and validity of recommended CMV serologic diagnostic algorithms.
 References

  1. TORCH. AACC: Lab Tests Online. https://labtestsonline.org/tests/torch. Updated September 22, 2020. Accessed March 3, 2021.

  2. Megli, Christina J, and Carolyn B Coyne. “Infections at the Maternal-Fetal Interface: An Overview of Pathogenesis and Defence.” Nature Reviews. Microbiology, Nature Publishing Group UK, 25 Aug. 2021, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386341/. 

  3. Wurcel, Victoria, et al. “The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems.” Public Health Genomics, vol. 22, no. 1-2, 2019, pp. 8–15., https://doi.org/10.1159/000501832. 

Logo Image

©2025 Abbott. Tutti i diritti riservati.

Tutti i marchi a cui si fa riferimento sono marchi commerciali del gruppo di società Abbott o dei rispettivi proprietari. Le foto sono riportate a scopo esclusivamente illustrativo. Eventuali persone raffigurate in tali foto possono essere dei modelli. Leggere la nota legale per ulteriori dettagli.

Tutti gli analizzatori ARCHITECT e gli strumenti Alinity hq, CELL-DYN Ruby e CELL-DYN Emerald 22 AL sono prodotti laser di classe I. ACCELERATOR APS e ACCELERATOR a3600 sono prodotti laser di classe II.

I sistemi Alinity, ARCHITECT e CELL-DYN sono destinati all'esecuzione di dosaggi diagnostici in vitro su campioni di origine umana. Leggere attentamente le istruzioni riportate nei manuali dei sistemi e le istruzioni sull'etichetta e/o dei reagenti.

Questo sito Web contiene informazioni generali sui nostri prodotti venduti in tutto il mondo. La disponibilità dei prodotti varia in base al Paese. Per la disponibilità dei prodotti nel proprio Paese, contattare il rappresentante Abbott locale. Alcuni prodotti descritti o alcune caratteristiche dei prodotti descritti in questa pagina globale potrebbero non essere disponibili sul mercato nel proprio Paese. Il contenuto è destinato esclusivamente ai professionisti sanitari.

State per uscire dai siti Web Abbott per accedere a un sito Web di terze parti.

I link che rimandano a pagine esterne ai siti Web internazionali di Abbott non sono sotto il controllo di Abbott che pertanto non è responsabile del relativo contenuto o di eventuali altri link in essi contenuti. Abbott fornisce questi link solo per motivi di praticità e l'inserimento dei suddetti link non implica l'approvazione dei siti corrispondenti da parte di Abbott. È possibile inoltre che il sito Web a cui si intende accedere non sia ottimizzato per il vostro schermo.

Volete continuare e uscire da questo sito Web?

State per entrare in un sito Web Abbott di un particolare Paese o regione.

Il sito Web richiesto è rivolto ai residenti di un particolare Paese o di particolari Paesi, come indicato su tale sito. Di conseguenza, il sito potrebbe contenere informazioni su farmaci, dispositivi medicali e altri prodotti o usi di prodotti che non sono approvati in altri Paesi o in altre aree geografiche.

Volete continuare e accedere a questo sito Web?

NO